|  |  |
| --- | --- |
|  |  |

**THE AMERICAN PARKINSON DISEASE ASSOCIATION SCIENTIFIC ADVISORY MEETS TO DETERMINE 2015-2016 RESEARCH FUNDING**

**May 30, 2015, New York, NY** – Earlier this month, the American Parkinson Disease Association Scientific Advisory Board (SAB) met to review more than sixty-two submissions all vying for more than a half million dollars in funding that will be awarded to experienced and young scientists in the Parkinson’s field.

 APDA is focused on advancing scientific research that will support its mission to *Find a Cure* for Parkinson’s disease. APDA has been at the forefront in funding most of the PD scientific discoveries in the last 50 years including the work of Dr. George C. Cotzias, which led to establishing the effectiveness of high oral doses of Levodopa in treating PD; the work of Dr. Roger Duvoisin and his team that led to identifying the role of heredity and environment in PD; the research of Dr. Menek Goldstein establishing the role of dopamine agonists in PD treatment; and the research at Robert Wood Johnson Medical Center, which led to the discovery of a mutation in the gene alpha-Synuclein, named PARK1.

“What sets APDA apart is it’s track record of launching the careers of the best and brightest scientists working on Parkinson’s disease, and enabling exploration of new ideas for finding the cure," commented Dr. David G. Standaert, Chairman of the SAB.

APDA's SAB is comprised of scientists with recognized expertise relevant to Parkinson's disease (PD) and leading edge research areas. Research grants are awarded at $50,000 per year and are available to junior investigators pursuing research in Parkinson’s disease, while the Post-Doctoral Fellowships are awarded at the $35,000 level to support post-doctoral scientists whose research training holds promise into new insights of geriatric psychology, pathophysiology, etiology and treatment of Parkinson’s disease.

Back row L-R) Joel S. Perlmutter, MD, Washington University School of Medicine; Un Jung Kang, MD, Columbia University College of Physicians and Surgeons; David G. Standaert, MD, PhD, Chairman, University of Alabama at Birmingham, School of Medicine; J. Timothy Greenamyre, MD, Ph.D., University of Pittsburgh Medical Center; Clemens R. Scherzer, MD, Harvard Medical School and Brigham & Women's Hospital; Mahlon R. DeLong, MD, Emory University School of Medicine; Dennis W. Dickson, MD, Mayo Clinic, Jacksonville

(Front row L-R) Marie Hélène Saint-Hilaire, MD, FRCP (C), Boston University School of Medicine; Mary Maral Mouradian, MD, Rutgers-Robert Wood Johnson Medical School; Evan Yale Snyder, MD, Ph.D, The Burnham Institute; Leslie A. Chambers, APDA President & CEO; Richard Myers, Ph.D., Boston University School of Medicine

(Not pictured) Marie-Francoise Chesselet, MD, PhD, UCLA David Geffen School of Medicine; Laura Marsh, MD, Michael E. DeBakey, VA Medical Center

This critical research funding is only possible because of generous donations from APDA’s steadfast supporters. However, none of this work would come to pass without the dedicated work of the SAB who gather on a regular basis to diligently review and recommend the most cutting edge research.

The SAB meeting also included research updates from four of the seven 2014-2015 junior investigators who each represent a vast diversity of research areas that can impact the treatment of PD.

**Samuel A. Frank, MD, of Boston University** is researching the question of mortality in Parkinson disease recognizing that the precise cause of death among people with the disease remains controversial. While at **Washington University in** **St Louis, PhD researcher, Jinbin Xu** is focused on develop imaging probes to visualize different aspects of neuroinflammation for PD diagnosis and therapy efficacy evaluation.  **Cristina Guardia Laguarta, PhD, from Columbia University** seeks to determine the exact localization of α-syn inside the cell to support the hypothesis that familial Parkinson’s disease may be due to overexpression of α-syn or its mutation. Finally, studying neuroprotective approaches to protecting or restoring the brain in PD, **Dr. Daniel Lawrence from the University of Michigan** is looking at the role that regulation of neurovascular responses play in the brain.

The announcement of 2015-2016 grant funding will take place in August.

###

CONTACT: Stephanie Paul | 718-981-8062 | spaul@apdaparkinson.org | www.apdaparkinson.org

**About the American Parkinson Disease Association**APDA was founded in 1961 with the dual purpose to *Ease the Burden - Find the Cure* for Parkinson’s disease. In that time, APDA has raised and invested more than $86 million to fund research, patient services and education, and elevate public awareness. As the country’s largest Parkinson’s grassroots organization, APDA is here to serve the more than one million Americans with Parkinson’s disease and their families through a nationwide network of Chapters, Information and Referral (I&R) Centers, and support groups. APDA also funds Centers for Advanced Research and awards grants to fund the most promising research toward discovering the cause(s) and finding the cure for Parkinson’s disease.